Head of Roche Pharmaceuticals
Appears in 1 story
Overseeing enicepatide's phase 3 program
Roche's experimental once-weekly diabetes injectable cut blood sugar and body weight in a 48-week phase 2 trial announced September 22. Patients on the highest 24 mg dose saw HbA1c drop 2.65 percentage points and weight fall 15.5%.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
